BasemWilliamMDMRCP(UK), FACP

Oncology • Columbus, OH

Hematologic Oncology

Hematologist/Oncologist, OhioHealth

Join to view full profile

Dr. William is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. William's full profile

Already have an account?

Office
500 Thomas Ln
Suite A3
Columbus, OH 43214
Phone+1 614-566-2500

Fax+1 614-533-0335

Summary

Hematology/Oncology, Blood and Marrow Transplant, Cellular Therapy, CAR-T, Lymphoma, Cutaneous Lymphoma, T-Cell Lymphoma, Drug Development, Clinical Investigator

Education & Training

University of Nebraska Medical Center College of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
UPMC Medical EducationResidency, Internal Medicine, 2002 - 2005
Ain Shams University Faculty of MedicineClass of 1996

Certifications & Licensure

OH State Medical License 2012 - 2025
CA State Medical License 2007 - 2023
IN State Medical License 2008 - 2013
NE State Medical License 2008 - 2012
NY State Medical License 2008 - 2010
VA State Medical License 2007 - 2010
MD State Medical License 2007 - 2009
ME State Medical License Active through 2009
DC State Medical License 2007 - 2008
PA State Medical License 2002 - 2005
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Fellow American College of Physicians, 2015
Membership of the Royal College of Physicians of the United Kingdom - MRCP(UK) 2005

Clinical Trials

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma Start of enrollment: 2009 Nov 12
Completed
Phase 1, Phase 2
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Oct 16
Completed
Phase 2
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2018 Mar 16
Active, not recruiting
Phase 2
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2018 Sep 10
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Impact of chronic graft--host disease on non-relapse mortality and survival.
Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Sumithira Vasu
Leukemia & Lymphoma. 2024-11-01
4 citations
A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help.
Kevin J Curran, Sarah Nikiforow, Carlos Bachier, Yen-Michael Hsu, David Maloney
Blood Advances. 2024-02-27
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Philip G Woost, Basem M William, Brenda W Cooper, Masumi Ueda Oshima, Folashade Otegbeye
Cytometry. Part B, Clinical Cytometry. 2024-01-01

Journal Articles

IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 Study
Pierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer

Abstracts/Posters

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma
Basem M. William, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018